Brief: Shenzhen Hepalink Pharmaceutical Group Sees FY Net Profit Attributable Rmb617 Mln- Rmb773 Mln
30/01/2023 14:40
Jan 30 (Reuters) - Shenzhen Hepalink Pharmaceutical
Group Co Ltd 002399.SZ :
* SEES FY NET PROFIT ATTRIBUTABLE TO BE RMB617.00 MILLION TO
RMB773.00 MILLION
* EXPECTED RESULTS DUE TO CO'S STEPPED UP EFFORTS TO OBTAIN
NEW
ORDERS, AMONG OTHERS
Source text for Eikon: ID:nHKS7H1kvl
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA